Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors
Open Access
- 4 April 2012
- journal article
- Published by Wiley in ChemMedChem
- Vol. 7 (6), 1101-1111
- https://doi.org/10.1002/cmdc.201100598
Abstract
Peroxisome proliferator‐activated receptors (PPARs) are a family of nuclear hormone receptors that control the expression of genes involved in a variety of physiologic processes, through heterodimerization with retinoid X receptor and complex formation with various cofactors. Drugs or treatment regimens that combine the beneficial effects of PPARα and γ agonism present an attractive therapeutic strategy to reduce cardiovascular risk factors. Aleglitazar is a dual PPARα/γ agonist currently in phase III clinical development for the treatment of patients with type 2 diabetes mellitus who recently experienced an acute coronary event. The potency and efficacy of aleglitazar was evaluated in a head‐to‐head comparison with other PPARα, γ and δ ligands. A comprehensive, 12‐concentration dose–response analysis using a cell‐based assay showed aleglitazar to be highly potent, with EC50 values of 5 nM and 9 nM for PPARα and PPARγ, respectively. Cofactor recruitment profiles confirmed that aleglitazar is a potent and balanced activator of PPARα and γ. The efficacy and potency of aleglitazar are discussed in relation to other dual PPARα/γ agonists, in context with the published X‐ray crystal structures of both PPARα and γ.Keywords
This publication has 52 references indexed in Scilit:
- Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human HepatocytesPLOS ONE, 2011
- Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5Nature, 2010
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysisThe Lancet, 2010
- INT131: A Selective Modulator of PPARγJournal of Molecular Biology, 2009
- Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetesDiabetes and Vascular Disease Research, 2007
- Modulation of PPAR activity via phosphorylationBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- Thiazolidinediones and their Fluid-Related Adverse EffectsDrug Safety, 2007
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Transcription coactivator TRAP220 is required for PPARγ2-stimulated adipogenesisNature, 2002
- Hepatotoxicity with ThiazolidinedionesDrug Safety, 2001